Talabostat in Treating Patients With Metastatic Kidney Cancer

Summary

RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well talabostat works in treating patients with metastatic kidney cancer.

Timeline

Start

2006-12

Primary completion

2007-05-30

Completion

2007-05-30

Outcome

Outcome not reported

Stopped: “safety reasons”

Drugs

Indications